Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
|
|
- Sheryl Fowler
- 6 years ago
- Views:
Transcription
1 Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK
2 Guardian guide for 2018: Top 5 UK medical school Penryn ESI
3 Risperidone Efficacy: BEHAVE-AD Ballard & Howard 2006 Nature Neuroscience Reviews Target symptom Mean Difference from placebo p value 95% CI Risperidone 1mg Psychosis p= to Risperidone 1mg Aggression p= to Risperidone 2mg Aggression p< to -0.95
4 STAR TRIAL: Zhong et al 2007 Quetpiapine 200mg (N=114) Quetiapine 100mg (N=120) Placebo (N=92) PANSS-EC -5.7 (0.9) -4.9 (0.8) -3.9 (0.9) NS NPI (total) -9.7 (2.2) -8.9 (2.1) -8.2 (2.4) NS Evaluation NPI (agitation) NPI (psychosis) -1.1 (0.5) -0.9 (0.5) -1.2 (0.5) NS -2.5 (0.9) -1.8 (0.8) -2.5 (0.9) NS CGIC 3.0 (0.2) 3.2 (0.2) 3.6 (0.2) NS
5 Major Adverse Outcomes with antipsychotics over 6-12 weeks (FDA, Schneider et al 2005,Ballard et al 2009) Parkinsonism Sedation Gait disturbance Increased respiratory infections Oedema Accelerated cognitive decline (2-4 fold) Stroke (>3 fold) Other thrombo-embolic events (up to 80%) Mortality ( fold)
6 Possible Interpretations Therapies Not good enough Small effect sizes Targets unclear Very heterogenous study populations Challenges with trial design Heterogenous trial populations Low entry thresholds Short duration No non pharmacological interventions doesn t follow best practice How rigorously have underlying medical causes and pain been excluded High placebo response Difficult to interpret major adverse events without a meta-analysis
7 Longer duration
8 Change from Baseline to 6 months DART AD Ballard et al PLOS Medicine 2008
9 DART AD: Differential Survival Ballard et al Lancet Neurology 2009 Differences in the survival rates in the DART-AD trial 80% Survival rate on placebo Survival rate on a antipsychotic 70% 60% 50% 40% 30% 20% 10% 0% Survival rate on placebo 71% 59% 53% Survival rate on a antipsychotic 46% 30% 26% Number of months The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Jan 2009
10 No Benefit and Accelerated Cognitive Decline with Quetiapine rivastigmine quetiapine placebo ChI v plac Nlp v plac Week 6 N=24 (15 completed SIB) N=26 (14 completed SIB) N=29 (17 completed SIB) Diff CMAI -8.3± ± ±17.2 T=0.4 P=0.67 T=0.3 P=0.74 Diff SIB +4.2± ± ±15.5 T=0.3 P=0.80 T=2.4 P=0.02* Week 26 N=24 (16 completed SIB) N=26 (15 completed SIB) N=29 (17 completed SIB) Diff SIB -1.1± ± ±18.1 T=0.5 P=0.61 T=2.3 P=0.03* Diff CMAI -10.5± ± ±16.6 T=0.5 P=0.62 T=0.1 P=0.87 AGIT-AD Ballard et al 2005 BMJ
11 Novel Statistical Approaches
12 Dextromethorphan/Quinidine (DM/Q) JAMA patient randomized to Dextromethorphan/Quinidine (DM/Q) or placebo in 10 week trial Complicated 3:4 randomization design with re-randomization of placebo non-responders after 5 weeks 88% completed trial Significant benefits in agitation/aggression and CGIC, with benefits evident from week 1 Falls and diarrhea were the main emergent adverse events (both <10%)
13 Non-Pharmacological Therapy
14 WHELD: Key Results Ballard et al Am J psychiatry 2016 AR significantly reduced antipsychotic use by 50% (OR 0.17, 95% CI 0.05 to 0.60, p=0.006). AR and SI significantly reduced mortality (OR=0.36, 95% CI 0.23 to 0.57, p<0.001) Benefits in mortality were achieved without a worsening of neuropsychiatric symptoms in people receiving AR and SI (-0.44, CI to 3.52, p=0.82) EX significantly improved depression (-4.74, CI 0.76 to 8.72) and neuropsychiatric symptoms (-4.01, 95% CI to -0.10, p=0.045). SI significantly improved quality of life (6.04, 95% CI 0.24 to 11.84, p=0.042) Combination of both SI and AR (p<0.04) and EX and AR (P<0.02) also significantly improved apathy
15 Brief Psychosocial Therapy (BPST ) in clinical trials Previous clinical trials of psychosis and behavioural symptoms in Alzheimer s Disease have experienced problems with high placebo response It is important to make sure a new drug is being tested in people who genuinely need it BPST is designed to mirror best practice guidelines and reduce the placebo response by identifying people who improve with a non-drug approach Only people who do not improve following BPST progress to pharmacological treatment In 3 previous trials of psychosis or agitation, has excluded 25% of people in run-in phase, but substantially reduced placebo response -with significant benefits compared to placebo in 2 of the trials (Howard et al 2007, Ballard et al 2009, Cummings et al 2014, Ballard et al 2017) Currently being used in 3 further ongoing clinical trials
16 How is the BPST delivered? Two - four week intervention to enable enjoyable activities between a person with dementia and their caregiver for minute a day Therapist works with a caregiver (care assistant or family member) over four sessions: Training (Day 1): in person (30-45 minutes) Follow-up (regular x 2*): by telephone (15 minutes) Baseline (Day 14-28): in person (15 minutes) Caregiver delivers the BPST to the patient Daily: min Completion of a simple diary Follow-up calls support and reinforce the caregiver *Schedules for each person with depend on screening period: Four weeks = weekly follow-up Two weeks = Follow up every 4 days
17 Discontinuation Design
18
19
20 Clear Criteria
21 Cummings et al 2017: IPA criteria for agitation Patients must meet criteria for cognitive impairment and exhibit behaviours such as excessive activity and verbal or physical aggression severe enough to produce disability in social, or interpersonal functions, or activities of daily living. These symptoms should not be attributable to other psychiatric or medical disorders, suboptimal environment, or drug effects. Future validation studies are needed to confirm or revise the definition. This definition will facilitate clinical trials and other types of clinical and translational research. New IPA Criteria for Agitation in Cognitive Impairment. Available from: eria_for_agitation_in_cognitive_impairment [
22 Modified CGIC
23 CitAD: JAMA 2014 OBJECTIVE: To evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: CitAD was a randomized, placebo-controlled, double-blind, parallel group trial with 186 patients with probable AD and clinically significant agitation INTERVENTIONS: Patients were randomized to receive a psychosocial intervention plus either citalopram (n = 94) or placebo (n = 92) for 9 weeks. Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability.
24 CitAD: Results MAIN OUTCOMES AND MEASURES: The NBRS-A estimated treatment difference (citalopram minus placebo) was (95% CI, to -0.06), P =.04. CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, ), P =.01 (Cohen s d standardized effect size 0.36). Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, Worsening of cognition (-1.05 points; 95% CI, to -0.13; P =.03) and QT interval prolongation (18.1 ms; 95% CI, ; P =.01) were seen in the citalopram group.
25 Central Rating
26 -020 Study: Pimavanserin Demonstrated Highly Significant Antipsychotic Efficacy (Lancet Feb 2014) 26 SAPS-PD (primary endpoint) (ITT, N=185; change from baseline) * **
27 SAPS-PD Score and Change from Baseline Subgroup Analysis (OC) (ITT Analysis Set) Subgroup: Screening MMSE < 25 Change from Baseline to Day 43 Placebo Pimavanserin N Mean (SE) (1.89) (1.81) Median
28 Improved trial design Clearer definition of agitation (and sub-syndromes) Non-pharmacological interventions to reduce placebo response Central rating of primary outcome to reduce impact of inter-rater variability New CGIC for neuropsychiatric symptoms Novel statistical approaches Discontinuation element to establish continued benefit Higher threshold for study entry Longer duration of trial (particularly for adverse events) Better targets (syndrome definition, molecular targets)
29 Contacts Clive Ballard: Byron Creese:
Management of Behavioral and Psychological Symptoms in People with Dementia Living in Care Homes: A UK Perspective
Management of Behavioral and Psychological Symptoms in People with Dementia Living in Care Homes: A UK Perspective Clive Ballard Professor of Age Related Diseases, King s College London And Director of
More informationAXS-05 Alzheimer s Disease Agitation R&D Day
NASDAQ: AXSM AXS-05 Alzheimer s Disease Agitation R&D Day October 18, 2018 AXS-05 and Unmet Needs in Alzheimer s Disease Agitation Introduction Mark Jacobson, Senior Vice President, Operations Axsome CNS
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationManaging agitation in dementia using non-pharmacological therapies
Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationPlease Join Us. International Psychogeriatric Association. Dependency Ratio. Geriatric Psychiatry in the 21st Century: A Global Perspective
International Psychogeriatric Association Please Join Us Geriatric Psychiatry in the 21st Century: A Global Perspective Jacobo Mintzer M.D. Executive Director Roper Saint Frances Clinical and Biotechnology
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationAppendix 2017UEMS031
Appendix 2017UEMS031 PREVENTION Clinical checklist This checklist should be completed for each person with dementia. Keep this chart with the person s corresponding paperwork. General symptoms Include
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationSupplementary Online Content
Supplementary Online Content Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized controlled trial. JAMA. doi:10.1001/jama.2014.93 eappendix.
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationAntipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses
658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:
More informationNeuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationLTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
More informationThe Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias
The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias The Patient and Carers Perspective Mary-Frances Morris, Trustee, Alzheimer Scotland.
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationAssessing and Treating Agitation Associated with Alzheimer s Disease
AXS-05 R&D Day April 24, 2018 Assessing and Treating Agitation Associated with Alzheimer s Disease Marc E. Agronin, MD VP, Behavioral Health and Clinical Research, Miami Jewish Health Affiliate Associate
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationArticles. Funding ACADIA Pharmaceuticals.
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study Clive Ballard,
More informationGuidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationAGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018.
AGITATION IN DEMENTIA BEHAVIORAL AND PSYCHIATRIC SYMPTOMS IN DEMENTIA (BPSD) AGITATION SUBGROUP SESSION 20 TH FEBRUARY 2018. BRIEF OVERVIEW: AGITATION ASSOCIATED WITH ALZHEIMER S DISEASE (AD) AD afflicts
More informationFROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 NEW RESEARCH FOCUSES ON TREATING NON-COGNITIVE SYMPTOMS OF PEOPLE WITH DEMENTIA
CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL
More informationFrom Neurodevelopment to Neurodegeneration: Behavioral Issues
From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to
More informationDelirium. Approach. Symptom Update Masterclass:
Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More informationTrial clinici nell anziano: efficacy or effectiveness?
LA SPERIMENTAZIONE FARMACOLOGICA CLINICA IN ETÀ GERIATRICA Trial clinici nell anziano: efficacy or effectiveness? Graziano Onder Fondazione Universitaria Policlinico A. Gemelli Università Cattolica del
More informationOlder People Mental Health - new directorate/new plans. Dr Adrian Treloar Clinical director
Older People Mental Health - new directorate/new plans Dr Adrian Treloar Clinical director Dementia 700,000 people in the UK currently have dementia; this number is set to double by 2038 1/3 of people
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationCritical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager
Critical Appraisal Practicum Fabio Di Bello Medical Implementation Manager fdibello@ebsco.com What we ll talk about today: DynaMed process for appraising randomized trials and writing evidence summaries
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationWorldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationDementia Prevention, Intervention and Care
Dementia Prevention, Intervention and Care What works and where do we need more research? Demensdagene 07/05/2018 Dr Andrew Sommerlad Wellcome Trust Research Fellow UCL Division of Psychiatry Declaration
More informationEffect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Research Original Investigation Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial Jeffrey L. Cummings, MD, ScD; Constantine G. Lyketsos,
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationAgitation in dementia. Gill Livingston
Agitation in dementia Gill Livingston And some of the team Gianluca Baio Julie Barber Claudia Cooper Briony Dow Paul Higgs Juanita Hoe Gerry Leavey Louise Marston Stephen Morris Rumana Omar Nishma Patel
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationTRANSPARENCY COMMITTEE Opinion 19 February 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated
More informationDementia: Rethinking our approach to behaviour
Dementia: Rethinking our approach to behaviour Dr Kathryn Lord Research Fellow 1 A bit about me: The 3 P s! Psychology Psychiatry Person centredcare 2 Challenging behaviours in Challenging behaviours dementia
More informationNKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information
NKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information Authors Sundhedsstyrelsen 1 1 [Empty affiliation] Citation example: S. NKR 55 demens og medicin
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationAssessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationParkinsonian Disorders with Dementia
Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University
More informationRisks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
More informationOptimising treatment and care for people with behavioural and psychological symptoms of dementia
Optimising treatment and care for people with behavioural and psychological symptoms of dementia A best practice guide for health and social care professionals Contents About this guide 3 Introduction
More informationWorldwide, over 40 million people have. Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 6, Number 1, 2019 Original Research The Author(s) Pimavanserin in Alzheimer s Disease Psychosis: Efficacy in Patients with More Pronounced
More informationVanderbilt & Qsource Webinar Series
Vanderbilt & Qsource Webinar Series Vanderbilt Medical Center Vanderbilt University Center for Quality Aging Qsource Session #1: Introduction to Dementia Care & QAPI Session #2: Dementia & Behavioral Disturbances
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationShriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences
Shriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences Disclosures Board Certified in Adult and Geriatric Psychiatry
More informationThe efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature
Review article: The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Dr. Ivan Netto 1, Aditya Iyer 2, Dr. Prathamesh
More informationAcetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia
STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationHow I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C)
How I Treat Aggression in Outpatients With Dementia C. Omelan MD, FRCP(C) Conflict of Interest I have no potential conflicts of interest to declare Overview Outline the prevalence of aggression Review
More informationPharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
International Psychogeriatrics (2013), 25:2, 185203 C International Psychogeriatric Association 2012.The online version of this article is published within an Open Access environment subject to the conditions
More informationOutlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.
Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that
More informationNumber of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month
Part V: Specific Behavior Scales-Sleep Scales Based on past month First 4 items ask for time or amount of sleep 41. Pittsburgh Sleep Quality Index (PSQI) Sleep quality Sleep latency Sleep duration Habitual
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationLong-Term Care Updates
Long-Term Care Updates March 2017 By Darren Hein, PharmD Nuedexta is a fixed combination of dextromethorphan, an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist,
More informationELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes
ELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes Anton P. Porsteinsson MD 1, Susan Abushakra MD 2, Merce Boada 3, Ira Goodman 4, Giovanni
More informationResponsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease
ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,
More informationDementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk.
Dementia: Managing Difficult Behaviors No conflicts of interest. Off-label medication use will be discussed during this talk. 1 Types of Neurocognitive Disorder Alzheimer s Disease Vascular Frontotemporal
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationParkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations
Parkinson s Disease Psychosis Treatment in Long-Term Care: Clinical and Operational Considerations Pari Deshmukh MD Triple board-certified psychiatrist (Boards of psychiatry, addiction medicine, integrative
More informationSurveillance report Published: 13 April 2017 nice.org.uk. NICE All rights reserved.
Surveillance report 2017 Antisocial behaviour and conduct disorders in children and young people: recognition and management (2013) NICE guideline CG158 Surveillance report Published: 13 April 2017 nice.org.uk
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationEvaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director
Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Objectives Differentiate between delirium, terminal restlessness, and dementia related agitation
More informationUp to 90% of people with dementia experience
Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people
More informationChoosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care
Choosing Wisely Psychiatry s Top Priorities for Appropriate Primary Care JASON BEAMAN D.O., M.S., FAPA ASSISTANT CLINICAL PROFESSOR CHAIR, DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES OKLAHOMA STATE
More information